ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Theratechnologies Inc. (THTX) stock declined over -1.91%, trading at $1.54 on NASDAQ, down from the previous close of $1.57. The stock opened at $1.53, fluctuating between $1.51 and $1.58 in the recent session.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Employees | 103 |
Beta | 1.47 |
Sales or Revenue | $81.76M |
5Y Sales Change% | 4.347% |
Fiscal Year Ends | November |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |